<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00527800</url>
  </required_header>
  <id_info>
    <org_study_id>CDC- PEPFAR CoAg#U62P024421</org_study_id>
    <nct_id>NCT00527800</nct_id>
  </id_info>
  <brief_title>Interactions Between HIV and Malaria in African Children</brief_title>
  <acronym>TCC</acronym>
  <official_title>Interactions Between HIV and Malaria in African Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Makerere University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The AIDS Support Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective cohort study where HIV-infected and uninfected children will be
      enrolled between 6 weeks and 9 months of age and followed to the age of 21 months. All
      HIV-infected children will be given trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis as of
      6 weeks of age. HIV-uninfected children born to HIV-infected mothers will be given TMP/SMX
      prophylaxis for the duration of breastfeeding and then randomized to the continuation of
      TMP/SMX or discontinuation of TMP/SMX prophylaxis. HIV-uninfected children born to
      HIV-uninfected mothers will not be given TMP/SMX prophylaxis. Study participants will be
      followed for all of their health care needs in a designated study clinic. All mother-child
      pairs will receive a basic care package including insecticide-treated bednets (ITNs) at
      enrollment. All HIV-infected mothers and children will receive antiretroviral therapy if
      eligible according to standardized World Health Organization (WHO) criteria. Study
      participants 4 months of age or older and at least 5 kg will be randomized to treatment with
      artemether-lumefantrine (AL) or dihydroartemisinin-piperaquine (DP) at the time of their
      first diagnosis of uncomplicated malaria. Study participants will receive the same
      antimalarial treatment regimen for all future episodes of uncomplicated malaria. Study
      participants less than 4 months of age or less than 5 kg diagnosed with malaria and all
      episodes of complicated malaria will be treated with quinine in accordance with local
      guidelines.

      The investigators will test the hypotheses that:

        1. TMP/SMX prophylaxis is highly effective in preventing malaria in both HIV-infected and
           HIV-uninfected children

        2. The use of TMP/SMX prophylaxis is associated with an increased risk of infection with
           malaria parasites containing antifolate resistance-conferring mutations.

        3. The use of antiretroviral (ARV) drugs is associated with a decreased incidence of
           malaria.

        4. The efficacy, safety, and tolerability of AL and DP for the treatment of uncomplicated
           malaria differ.

           In 2008, we received approval and funding to extend the trial until 2012. We are now
           following all children through 5 years of age. First randomization to continue or
           discontinue TMP/SMX prophylaxis in our HIV-exposed population occurs 6-8 weeks after
           cessation of breastfeeding when HIV status can be confirmed as negative by DNA PCR. A
           second randomization occurs at 2 years of age in our HIV-exposed participants. At that
           point all HIV-exposed children who were originally randomized to continue TMP/SMX
           prophylaxis are again randomized to either immediately discontinue TMP/SMX prophylaxis
           or continue prophylaxis until age 4 years. All children will be off TMP/SMX between 4
           and 5 years of age.

           We have also added an additional hypothesis to test during the study extension:

        5. Prolonged TMP/SMX prophylaxis will result in an increased incidence of malaria in
           children in the year immediately following cessation of prophylaxis compared to children
           who have not used prophylaxis for over a year and those who have never been on
           prophylaxis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of clinical episodes of malaria</measure>
    <time_frame>over entire course of follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk of treatment failure at Day 28 defined as any early treatment failure or late clinical/parasitological failure adjusted and unadjusted by genotyping to distinguish recrudescence (treatment failure due to drug resistance) and new infections</measure>
    <time_frame>28 days following each malaria treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of mutations known to confer resistance to antifolate drugs in pretreatment samples from patients diagnosed with malaria</measure>
    <time_frame>each time episode of malaria is diagnosed</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of adverse events</measure>
    <time_frame>28 days following each malaria treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">351</enrollment>
  <condition>Malaria</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment for episodes of uncomplicated malaria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment for uncomplicated malaria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prevention of malaria in HIV uninfected, exposed children</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Prevention of malaria in HIV uninfected, exposed children</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dihydroartemisinin-piperaquine</intervention_name>
    <description>Once daily for 3 days, given in fixed dose tablets (40 mg dihydroartemisinin + 320 mg piperaquine) according to weight-based guidelines</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether-lumefantrine</intervention_name>
    <description>Dosed twice daily for 3 days, given in fixed dose tablets (20 mg artemether + 120 mg lumefantrine) according to weight-based guidelines</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimethoprim-sulfamethoxazole</intervention_name>
    <description>Once daily dosing according to weight based guidelines</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 6 weeks to 9 months

          2. Documented HIV-1 status of mother and child

          3. Agreement to come to the study clinic for any febrile episode or other illness

          4. Agreement to avoid medications administered outside the study protocol

          5. Guardian age 18 years or older (no age limit for parents)

          6. Parent or guardian willing to provide informed consent

          7. Residence within a 30 km radius of the study clinic

        Exclusion Criteria:

          1. HIV-exposed infants who have already stopped receiving TMP/SMX as a result of having
             stopped breastfeeding and having been tested HIV-negative before screening

          2. Intention to move more than 30 km from the study clinic during the follow-up period

          3. History of allergy or sensitivity to AL or DP or TMP/SMX

          4. Active medical problem requiring in-patient evaluation at the time of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>9 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grant Dorsey, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tororo District Hospital</name>
      <address>
        <city>Tororo</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <link>
    <url>http://www.muucsf.org/</url>
    <description>MU-UCSF Research Collaboration website</description>
  </link>
  <results_reference>
    <citation>Creek DJ, Bigira V, McCormack S, Arinaitwe E, Wanzira H, Kakuru A, Tappero JW, Sandison TG, Lindegardh N, Nosten F, Aweeka FT, Parikh S. Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infants. J Infect Dis. 2013 Jun 1;207(11):1646-54. doi: 10.1093/infdis/jit078. Epub 2013 Feb 27.</citation>
    <PMID>23447696</PMID>
  </results_reference>
  <results_reference>
    <citation>Kakuru A, Jagannathan P, Arinaitwe E, Wanzira H, Muhindo M, Bigira V, Osilo E, Homsy J, Kamya MR, Tappero JW, Dorsey G. The effects of ACT treatment and TS prophylaxis on Plasmodium falciparum gametocytemia in a cohort of young Ugandan children. Am J Trop Med Hyg. 2013 Apr;88(4):736-43. doi: 10.4269/ajtmh.12-0654. Epub 2013 Feb 4.</citation>
    <PMID>23382157</PMID>
  </results_reference>
  <results_reference>
    <citation>Jagannathan P, Muhindo MK, Kakuru A, Arinaitwe E, Greenhouse B, Tappero J, Rosenthal PJ, Kaharuza F, Kamya MR, Dorsey G. Increasing incidence of malaria in children despite insecticide-treated bed nets and prompt anti-malarial therapy in Tororo, Uganda. Malar J. 2012 Dec 28;11:435. doi: 10.1186/1475-2875-11-435.</citation>
    <PMID>23273022</PMID>
  </results_reference>
  <results_reference>
    <citation>Arinaitwe E, Gasasira A, Verret W, Homsy J, Wanzira H, Kakuru A, Sandison TG, Young S, Tappero JW, Kamya MR, Dorsey G. The association between malnutrition and the incidence of malaria among young HIV-infected and -uninfected Ugandan children: a prospective study. Malar J. 2012 Mar 27;11:90. doi: 10.1186/1475-2875-11-90.</citation>
    <PMID>22453048</PMID>
  </results_reference>
  <results_reference>
    <citation>Sandison TG, Homsy J, Arinaitwe E, Wanzira H, Kakuru A, Bigira V, Kalamya J, Vora N, Kublin J, Kamya MR, Dorsey G, Tappero JW. Protective efficacy of co-trimoxazole prophylaxis against malaria in HIV exposed children in rural Uganda: a randomised clinical trial. BMJ. 2011 Mar 31;342:d1617. doi: 10.1136/bmj.d1617.</citation>
    <PMID>21454456</PMID>
  </results_reference>
  <results_reference>
    <citation>Verret WJ, Arinaitwe E, Wanzira H, Bigira V, Kakuru A, Kamya M, Tappero JW, Sandison T, Dorsey G. Effect of nutritional status on response to treatment with artemisinin-based combination therapy in young Ugandan children with malaria. Antimicrob Agents Chemother. 2011 Jun;55(6):2629-35. doi: 10.1128/AAC.01727-10. Epub 2011 Mar 7.</citation>
    <PMID>21383095</PMID>
  </results_reference>
  <results_reference>
    <citation>Creek D, Bigira V, Arinaitwe E, Wanzira H, Kakuru A, Tappero J, Kamya MR, Dorsey G, Sandison TG. Increased risk of early vomiting among infants and young children treated with dihydroartemisinin-piperaquine compared with artemether-lumefantrine for uncomplicated malaria. Am J Trop Med Hyg. 2010 Oct;83(4):873-5. doi: 10.4269/ajtmh.2010.10-0158.</citation>
    <PMID>20889882</PMID>
  </results_reference>
  <results_reference>
    <citation>Vora N, Homsy J, Kakuru A, Arinaitwe E, Wanzira H, Sandison TG, Bigira V, Kamya MR, Tappero JW, Dorsey G. Breastfeeding and the risk of malaria in children born to HIV-infected and uninfected mothers in rural Uganda. J Acquir Immune Defic Syndr. 2010 Oct;55(2):253-61. doi: 10.1097/QAI.0b013e3181eb4fd7.</citation>
    <PMID>20683193</PMID>
  </results_reference>
  <results_reference>
    <citation>Katrak S, Gasasira A, Arinaitwe E, Kakuru A, Wanzira H, Bigira V, Sandison TG, Homsy J, Tappero JW, Kamya MR, Dorsey G. Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children. Malar J. 2009 Nov 30;8:272. doi: 10.1186/1475-2875-8-272.</citation>
    <PMID>19948038</PMID>
  </results_reference>
  <results_reference>
    <citation>Arinaitwe E, Sandison TG, Wanzira H, Kakuru A, Homsy J, Kalamya J, Kamya MR, Vora N, Greenhouse B, Rosenthal PJ, Tappero J, Dorsey G. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin Infect Dis. 2009 Dec 1;49(11):1629-37. doi: 10.1086/647946.</citation>
    <PMID>19877969</PMID>
  </results_reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2007</study_first_submitted>
  <study_first_submitted_qc>September 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2007</study_first_posted>
  <last_update_submitted>October 9, 2013</last_update_submitted>
  <last_update_submitted_qc>October 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malaria</keyword>
  <keyword>HIV</keyword>
  <keyword>Trimethoprim-sulfamethoxazole</keyword>
  <keyword>Artemether-lumefantrine</keyword>
  <keyword>Dihydroartemisinin-piperaquine</keyword>
  <keyword>Acute Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Piperaquine</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Artemether-lumefantrine combination</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Dihydroartemisinin</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

